Zhen‐Huan Hu

Anhui Jianzhu University — China

Medicine · Health Sciences

26h-index3.3kcitations111works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(44), Acute Myeloid Leukemia Research(26), Chronic Myeloid Leukemia Treatments(23), Chronic Lymphocytic Leukemia Research(21), Lymphoma Diagnosis and Treatment(20)

Publications111 total

Impact of Digital Transformation on Corporate Performance in the Construction Industry
Journal of Construction Engineering and Management·2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Blood Advances·2025· 7 citedOpen Access
Establishment of a real-time fluorescent recombinase polymerase amplification (RT-RPA) assay for BCR-ABL fusion gene detection
Blood&Genomics·2025Open Access
455 | BENDAMUSTINE AS LYMPHODEPLETING CHEMOTHERAPY PRIOR TO AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025Open Access
143 | REAL‐WORLD OUTCOMES OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) FOR THE TREATMENT OF RICHTER TRANSFORMATION TO LARGE B‐CELL LYMPHOMA (RT‐LBCL)
Hematological Oncology·2025· 1 citedOpen Access
Genome-Wide Identification and Expression Profiling of Dehydration-Responsive Element-Binding Family Genes in Flax (Linum usitatissimum L.)
International Journal of Molecular Sciences·2025· 1 citedOpen Access
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
Journal of Clinical Oncology·2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Blood Advances·2025· 13 citedOpen Access
Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Blood·2024· 1 cited
Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Blood·2024· 9 citedOpen Access
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
Blood·2024· 2 citedOpen Access
Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
Blood·2024· 3 citedOpen Access
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
UNC Libraries·2024· 1 citedOpen Access
“Don't keep me waiting”: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes
Blood Advances·2024· 6 citedOpen Access
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Blood·2024· 24 citedOpen Access
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor <scp>ECOG</scp> performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy
American Journal of Hematology·2024· 3 citedOpen Access
Contemporary Treatment Options Beyond Chimeric Antigen Receptor (CAR) T-Cell Therapies for Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): A Systematic Literature Review (SLR)
Transplantation and Cellular Therapy·2024
Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)
Transplantation and Cellular Therapy·2024· 1 cited
Minority Patients Receiving CAR T Therapy in the US between 2020−2025: A SEER-Based Projection on Racial Composition and Impact of Proximity to Authorized Treatment Centers
Transplantation and Cellular Therapy·2024
Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data
Blood·2023· 1 cited
page 1 of 6Next →

Frequent Co-authors

Marcelo C. Pasquini(26), Wael Saber(24), Frederick L. Locke(15), Mahmoud Aljurf(15), Uday Popat(15), Bipin N. Savani(14), Baldeep Wirk(14), Taiga Nishihori(14), Edwin P. Alyea(14), Caron A. Jacobson(13), Robert Peter Gale(13), Ronald Sobecks(13), Sarah Nikiforow(12), Richard F. Olsson(12), Mark R. Litzow(11), Ulrike Bacher(11), Miguel‐Angel Perales(10), Sairah Ahmed(10), Kwang Woo Ahn(10), Mehdi Hamadani(10)